Voluntary Health Organizations (U.S.) — NAICS 813212

An investor's primer. NAICS = North American Industry Classification System, the U.S. government's standard code for an industry.

1. Overview

Voluntary health organizations are the disease-focused charities most Americans know by name — the American Heart Association, the American Cancer Society, the Alzheimer's Association, the Cystic Fibrosis Foundation. Their job, in Census terms, is "raising funds for health-related research, disease prevention, health education, and patient services." [4] They are the private, philanthropy-funded layer of the U.S. health system: they pay for research the government and drug companies don't, run patient-support and awareness programs, and lobby on health policy.

Why anyone allocating capital should care: this is a real economic sector — roughly $29 billion in annual revenue and 57,000 paid employees [1][2] — but it is built almost entirely out of 501(c)(3) tax-exempt nonprofits (the section of the Internal Revenue Service tax code that defines charities). That has a hard consequence: there is no stock to buy and no owner to pay. These organizations have no shareholders and cannot distribute earnings to private individuals. [19] So the ways in for both public-market and private investors are all indirect — the software, payments, and services vendors that run charity fundraising, and, more interestingly, the biopharma companies and drug-royalty streams that charity "venture philanthropy" helped create. More on both below.

The central question for an investor is therefore not "who has the highest profit margin?" It is "who owns donor trust, recurring relationships, useful data, and efficient distribution?"

2. What it is and how it's structured

In scope (813212): nonprofit organizations whose primary activity is raising money for a health cause and channeling it into research grants, prevention, education, and patient services — heart, cancer, diabetes, Alzheimer's, cystic fibrosis, multiple sclerosis, and hundreds of smaller disease groups. [4]

What it excludes (named adjacent NAICS codes — this matters, because the boundaries are where the statistics get fuzzy): [4]

• Grantmaking foundations and charitable trusts that give away an endowment rather than solicit the public — NAICS 813211.
• Other (non-health) social-welfare fundraisers — NAICS 813219.
• Fundraising on a contract or fee basis (professional solicitors and fundraising counsel) — NAICS 561499; and telemarketing bureaus — NAICS 561422.
• Organizations that primarily do the health research themselves (medical and university research labs) — NAICS 54171 / 611310.
• Hospitals that actually deliver care — NAICS 622.
• Political organizations (NAICS 813940) and social-advocacy organizations (NAICS 81331).

The line is blurry for hybrids, and that is where the money is. St. Jude Children's Research Hospital is a hospital (622), but its fundraising arm, ALSAC (American Lebanese Syrian Associated Charities), is a public-solicitation machine that raised roughly $2.5 billion in FY2024 [17] and behaves exactly like an 813212 organization. Where a giant like that lands in the official statistics depends on how it files.

Ownership is governance, not equity. The mix is effectively 100% nonprofit — no government ownership, no for-profit ownership, no publicly traded pure-plays. Structurally, most large ones are a single national 501(c)(3) with a network of local chapters/affiliates and, often, a paired 501(c)(4) advocacy arm for lobbying (e.g., the American Cancer Society Cancer Action Network). [7] "Public charities" like these draw broad public support, which distinguishes them from private foundations (813211) that lean on a handful of major donors. [19]

3. How big it is

Federal figures for NAICS 813212 (dollars converted from the source's thousands-of-dollars units):

(SBA = U.S. Small Business Administration; its $34M threshold is a program-eligibility cutoff, not a market-size estimate.)

Concentration is moderate-to-low. The four largest firms take 37.2% of revenue, the top eight 44.7%, the top twenty 57.1%, and the top fifty 69.2%. [2] The Herfindahl-Hirschman Index (HHI) — a standard concentration score — is just 447.9, far below the 1,500 mark that U.S. Department of Justice / Federal Trade Commission merger guidance treats as "unconcentrated." [2][32] Translation: a handful of household-name giants sit on top, followed by a very long tail of mid-size and small disease charities. The comparison is directional, though — 813212 is a statistical category, not necessarily a single competitive market.

The undercount caveat. These counts capture nonprofits with paid employees, and they capture them fairly well — this is not an industry hidden inside government budgets or run by untracked sole proprietors. Two real gaps remain. First, a vast layer of all-volunteer local health groups with no payroll falls outside the employer statistics entirely. Second, and more important, the $29.2 billion depends on where hybrids file — research hospitals, university labs, and health-focused foundations sit in adjacent codes, so a St. Jude/ALSAC-scale organization may or may not be inside the figure. For scale, total U.S. charitable giving to the broad "health" category (which also includes hospitals and research institutes) was $60.5 billion in 2024 — about 10% of all U.S. giving. [5] The 813212 slice is a large piece of that, not the whole. Our federal file carries no donor-count, donor-retention, fundraising-cost, endowment, or program-expense aggregate for the industry — those are not available here and are not estimated.

4. The "investable universe" (there are no shares in the operators — read this carefully)

No voluntary health organization is publicly traded. They are 501(c)(3) charities with no equity, and — unlike hospitals — they rarely issue public bonds. The largest operators, ranked by most recent reported total revenue:

(JDRF = Juvenile Diabetes Research Foundation; T1D = type 1 diabetes.) These are the operators, held for mission by boards — not by conventional owners.

So how does listed capital get exposure? One step removed — two seams:

A. The fundraising / payments infrastructure that sells to these charities.

B. The venture-philanthropy winners. Some charities fund drug development and share in the upside. Vertex Pharmaceuticals (Nasdaq: VRTX) built its cystic-fibrosis franchise on science the Cystic Fibrosis Foundation seeded; the Foundation later sold its resulting drug royalties to Royalty Pharma (Nasdaq: RPRX) for $3.3 billion in 2014 — roughly ten times its normal annual revenue. [10] That is the single most investment-relevant fact in this industry, and the model other foundations now chase.

Private-market exposure is more direct in the enabling technology (all privately held):

• GoFundMe Pro (formerly Classy) — nonprofit campaign, event, and peer-to-peer fundraising tools. [27]
• Bonterra — nonprofit and social-impact software, backed by Apax funds. [28]
• Bloomerang — donor-CRM roll-up backed by JMI Equity and Warburg Pincus; combined with Qgiv. [29]

For private investors / family offices, the "position" is usually philanthropic — direct gifts, donor-advised funds (DAFs), charitable gift annuities, bequests. But the venture-philanthropy seam is genuinely investable: foundations co-invest alongside biotech venture funds, and the resulting drug royalties get sold to buyers like Royalty Pharma. A private investor can sit on the buy side of those royalty sales, back the software/payments vendors, or provide mission-related loans and program-related investments (PRIs) to health nonprofits. This is where actual financial returns appear in a sector that otherwise pays no dividend — and diligence should treat recoverable grants and PRIs as distinct from equity.

5. How the money works

No profit is distributed; the "surplus" a charity earns is recycled into programs and reserves. The economic engine is simple to state: raise a dollar for well under a dollar of cost, then deploy it — and, for a few, convert research bets into royalty streams.

Revenue mix (the levers):

• Individual donations and bequests — the base. Contributions are ~70% of the American Heart Association's revenue [6] and 95%+ of the National MS Society's. [13]
• Special events / peer-to-peer (P2P) fundraising — the Heart Walk, Relay For Life, Bike MS, Walk to End Alzheimer's. Supporters raise money from their own networks; the charity supplies the brand and logistics.
• Corporate sponsorships and cause-marketing partnerships; employee matching-gift programs.
• Foundation and government grants.
• Earned/program revenue — e.g., the American Heart Association sells CPR (cardiopulmonary resuscitation) training materials, booking $108 million in net inventory sales and $69 million in royalties in FY2024. [6]
• Investment income on reserves and endowments — which rises and falls with markets. Strong 2024 stock returns lifted giving sector-wide. [5]
• Venture-philanthropy royalties — the outlier, dominated by the Cystic Fibrosis Foundation's Vertex windfall. [10]

The core "unit economics" is fundraising efficiency — the program-expense ratio (share of spending that reaches the mission) and its mirror, the cost to raise a dollar. Watchdogs treat this as the industry's operating-margin equivalent: CharityWatch rates a group "efficient" at 75%+ on programs; BBB Wise Giving Alliance requires 65%; Charity Navigator looks for roughly 70%+. [21] A charity that spends 80 cents of every dollar on programs is the sector's version of a low-cost operator — but the ratio alone is not the whole story (see §7).

The other core metric is the donor base itself — new-donor acquisition, retention, and lifetime value, exactly like subscriber economics. Sector-wide donor retention was 42.9% in 2024, meaning most donors don't give again the next year, so acquisition is a constant, costly treadmill. [18] Other operating levers worth reading on a Form 990 or audit: unrestricted vs. restricted revenue (restricted dollars can be booked before they are usable), pledge collection and cash conversion, major-donor and corporate-sponsor concentration, reserves and spending policy, and data/cyber controls.

6. What drives demand

"Demand" here means the willingness of donors, sponsors, and grantmakers to give:

• Disease burden and an aging population. Heart disease and cancer remained the two leading causes of U.S. death in 2024 [33]; more Alzheimer's, cancer, and diabetes cases enlarge the affected community that donates and volunteers.
• Personal connection — the strongest fundraising driver is a donor's own family experience with the disease.
• The wealth and stock-market cycle — giving tracks household wealth. 2024's market gains pushed total U.S. giving to a record $592.5 billion, up 6.3% in current dollars and 3.3% after inflation. [5] That total spans all causes, not just 813212, but it shows the macro-sensitivity of the funding pool.
• Corporate CSR budgets and cause-marketing appetite; employee giving and matching.
• Salience moments — new Alzheimer's drugs, GLP-1 diabetes/obesity breakthroughs, or a celebrity diagnosis spike attention and dollars for the relevant cause.
• Tax policy — donations are deductible only for taxpayers who itemize; the 2017 rise in the standard deduction shrank the itemizing pool and pressured small-donor giving. [19]
• Digital, mobile, recurring, and peer-to-peer channels that lower the cost of asking.

7. Regulation

• Federal (IRS): organizations must qualify as 501(c)(3) charities and file an annual, publicly available Form 990 disclosing revenue, expenses, and executive pay. Failing to file for three consecutive years triggers automatic loss of tax-exempt status. [19][30] Charitable-purpose and no-private-benefit rules apply, campaign politicking is prohibited, and lobbying is limited (hence the separate 501(c)(4) advocacy arms). [30]
• State: 41 states plus the District of Columbia require charitable-solicitation registration before a group can ask residents for money, and many mandate donor-disclosure language, plus separate compliance for paid solicitors and fundraising counsel. [19][20] State attorneys general oversee charitable assets and are the front line against fraud.
• Enforcement: the Federal Trade Commission and state AGs pursue sham-charity fraud — the recurring scandal risk for the whole sector's trust.
• Health-data rules: the Health Insurance Portability and Accountability Act (HIPAA) binds "covered entities" and their business associates, not automatically every voluntary health organization — but any group handling protected health information still faces contractual, privacy, and security obligations. [31]
• De facto regulation by watchdogs: Charity Navigator, CharityWatch, BBB Wise Giving Alliance, and Candid/GuideStar ratings function like a credit-rating layer; a downgrade or a high-overhead label can cut donations. Notably, the big raters jointly warned in 2013 against judging charities on overhead ratio alone — the "overhead myth" — pushing toward outcomes-based evaluation. [21]

For an investor, compliance quality is an operating asset: a registration lapse, misleading appeal, governance failure, or data breach can erase donor trust faster than it would dent a conventional consumer brand.

8. Competitive dynamics and consolidation

Charities don't compete on price; they compete for donor dollars, corporate sponsors, grant funding, volunteers, and attention. Awareness itself is a battlefield — ribbon colors, awareness months, and brand recognition are moats. Barriers to entry are low (a 501(c)(3) is easy to form), but barriers to scale — trust, brand, donor data, scientific-review credibility, and a national event infrastructure — are high, which is why the same names dominate for decades even though the reported field is statistically fragmented (HHI 447.9). [2]

Consolidation is real and accelerating in form:

• National consolidation of chapter networks: the American Cancer Society folded its regional divisions into a single national entity [7]; Susan G. Komen similarly absorbed its affiliate network.
• Rebrands to stay relevant: JDRF became Breakthrough T1D (2024) [11]; the Leukemia & Lymphoma Society became Blood Cancer United (2025). [12]
• Mergers of smaller disease groups to gain scale as fundraising costs rise.

The strategic prize everyone is chasing is the Cystic Fibrosis Foundation's venture-philanthropy model — investing donor money into drug development and capturing the financial upside. Breakthrough T1D, Blood Cancer United, and the Michael J. Fox Foundation have all adopted versions of it. [10]

Judgment: large charities are more likely to combine through affiliation, shared services, chapter restructuring, or merger than through equity takeovers (there is no equity to take). The classic private-equity consolidation is happening one layer out — in the vendors: Classy folded into GoFundMe Pro, and Bloomerang combined with Qgiv. [27][29]

9. Risks

• A shrinking, top-heavy donor base. The number of U.S. donors fell 4.5% in 2024, with small donors (under $100) down 8.8%; the sector increasingly leans on a few large donors — concentration risk that makes any single year volatile. [18]
• Economic cyclicality. Recessions, falling markets, and weaker household income cut discretionary giving and major gifts. [5]
• Reputational / fraud risk. Trust is the entire product; one scandal or a high-overhead exposé can collapse giving.
• Restricted-funding mismatch. Revenue may be booked before the organization has flexible cash for general operations.
• Cybersecurity and privacy. Donor records, payment data, and health information are attractive targets; Blackbaud itself flags data-security failures as a material business risk after its 2020 breach. [23]
• Event-model fatigue. Walks, rides, and galas have not fully recovered pre-2020 participation, threatening the peer-to-peer engine.
• Market risk on reserves and endowments — investment income swings with equities. [6]
• Federal research-funding volatility. Cuts to the National Institutes of Health raise pressure on private disease funders to fill gaps just as their own revenue is strained.
• Competition from DAFs and direct giving, which can route money around traditional charities; and platform dependence for smaller groups reliant on one vendor or processor.
• Tax-policy and demographic shifts — fewer itemizers, and younger donors who give differently than the aging core supporter base. [19]
• Mission risk — a medical breakthrough can cut the urgency of one disease campaign even as it opens new ones.

10. How to invest, and the outlook

Public-market routes (all indirect):

• Fundraising / payments infrastructure — Blackbaud (Nasdaq: BLKB, subject to a possible Clearlake take-private), plus diversified names with charity exposure (Salesforce, PayPal, Visa, Mastercard). Screen these on recurring software revenue, customer retention, cybersecurity, and sensitivity to nonprofit budgets — not on a "health-philanthropy" thesis they don't purely represent. [22][23][24][25][26]
• Venture-philanthropy beneficiaries — Vertex Pharmaceuticals (Nasdaq: VRTX) and Royalty Pharma (Nasdaq: RPRX), the clearest listed links to the CF Foundation's success. [10]

Private-capital routes:

• Direct philanthropy, donor-advised funds, charitable gift annuities, and bequests (the standard channels).
• The real return-bearing seam: co-investing alongside charity venture-philanthropy funds, buying the drug royalties they generate, and program-related lending to health nonprofits — plus backing the private software/payments vendors (GoFundMe Pro, Bonterra, Bloomerang and peers). Diligence there mirrors any software/PE deal: recurring revenue, churn, donor-data ownership, implementation cost, platform dependence, integration risk, and privacy controls. When underwriting a nonprofit directly, read audited statements and Form 990s for restricted-vs-unrestricted assets, donor concentration, reserves, governance, program outcomes, and state registrations.

Outlook (forward-looking judgment, not reported fact): The near-term picture is a squeeze on the top line — a shrinking, top-heavy donor base and lingering event fatigue — set against record aggregate giving and a maturing venture-philanthropy playbook that gives the best-run foundations a durable, non-donation revenue source. The long-run demand base is durable: aging, chronic disease, and patient-support needs don't go away. Expect more national consolidation, more rebrands, and more foundations trying to replicate the CF Foundation's royalty windfall. Three variables to watch: donor-retention trends [18], the trajectory of federal biomedical research funding, and whether the venture-philanthropy-to-royalty model produces a second blockbuster on the scale of cystic fibrosis. For a public-market investor, the most investable opportunities sit around the industry — in software, payments, data, and digital fundraising, and in the biopharma/royalty names — rather than in the charities themselves.

---

Sources

1. U.S. Census Bureau. County Business Patterns, 2023 — NAICS 813212 (establishments, employment, payroll). 2025. https://www.census.gov/data/datasets/2023/econ/cbp/2023-cbp.html
2. U.S. Census Bureau. 2022 Economic Census, Establishment and Firm Size / Concentration by Largest Firms — NAICS 813212 (receipts, firm count, concentration ratios, HHI). 2022. https://www.census.gov/programs-surveys/economic-census.html
3. U.S. Small Business Administration. Table of Small Business Size Standards (NAICS 813212 = $34M). 2023. https://www.sba.gov/document/support-table-size-standards
4. U.S. Census Bureau. 2022 NAICS Definition & Manual — 813212 Voluntary Health Organizations (scope and cross-references). 2022. https://www.census.gov/naics/?input=813212&year=2022
5. Giving USA Foundation & Indiana University Lilly Family School of Philanthropy. Giving USA 2025: U.S. charitable giving grew to $592.50 billion in 2024 (Health subsector $60.51 billion). 2025. https://givingusa.org/giving-usa-2025-u-s-charitable-giving-grew-to-592-50-billion-in-2024-lifted-by-stock-market-gains/
6. ProPublica Nonprofit Explorer. American Heart Association Inc — Form 990 (FY ending June 2025 and June 2024). 2025. https://projects.propublica.org/nonprofits/organizations/135613797
7. American Cancer Society. 2024 Combined Financial Statements; Financials & Governance. 2024. https://www.cancer.org/about-us/financial-governance-information/combined-financial-statements/2024.html
8. Alzheimer's Association. Fiscal Year 2024 Annual Report (July 1, 2023 – June 30, 2024). 2024. https://www.alz.org/about/annual-report
9. ProPublica Nonprofit Explorer. Michael J. Fox Foundation for Parkinson's Research — Form 990 (FY2024). 2024. https://projects.propublica.org/nonprofits/organizations/134141945
10. Cystic Fibrosis Foundation, Our Venture Philanthropy Model; and Chemical & Engineering News, "Cystic Fibrosis Foundation Gets $3.3 Billion For Royalties." 2014/2024. https://www.cff.org/about-us/our-venture-philanthropy-model — https://cen.acs.org/articles/92/i47/Cystic-Fibrosis-Foundation-33-Billion.html
11. Breakthrough T1D (formerly JDRF). FY2024 Audited Financial Statements / financial overview. 2024. https://www.breakthrought1d.org/about/financials/
12. Blood Cancer United (formerly Leukemia & Lymphoma Society). Financials and 2024 Annual Report (rebrand). 2024/2025. https://www.lls.org/financials
13. ProPublica Nonprofit Explorer. National Multiple Sclerosis Society — Form 990 (FY ending September 2024). 2024. https://projects.propublica.org/nonprofits/organizations/135661935
14. ProPublica Nonprofit Explorer. American Diabetes Association Inc — Form 990 (FY2024). 2024. https://projects.propublica.org/nonprofits/organizations/131623888
15. American Lung Association. FY2023 Form 990 (public disclosure copy). 2023. https://www.lung.org/getmedia/aaae82f9-60c7-46cb-9050-ad3460f108a7/FY23-990-Public-Disclosure-Copy.pdf
16. Wikipedia. Susan G. Komen (revenue, FY2022–2023). 2024. https://en.wikipedia.org/wiki/Susan_G._Komen
17. St. Jude Children's Research Hospital / ALSAC. Combined Financial Statements, Fiscal Year 2024. 2024. https://www.stjude.org/content/dam/en_US/shared/www/about-st-jude/financial-information/alsac-st-jude-combined-financial-statement-fiscal-year-2024.pdf
18. Association of Fundraising Professionals / Fundraising Effectiveness Project. Q4 2024 Quarterly Benchmark Report (donor count −4.5%, small donors −8.8%, retention 42.9%). 2025. https://afpglobal.org/news/fep-data-q4-2024-highlights-growing-role-high-dollar-donors-driving-fundraising-performance
19. Internal Revenue Service. Charitable Organizations — Charitable Contributions, Form 990, and Charitable-Solicitation State Requirements. 2024. https://www.irs.gov/charities-non-profits/charitable-organizations/charitable-solicitation-state-requirements
20. National Council of Nonprofits. Charitable Solicitation Registration (41 states + D.C.). 2024. https://www.councilofnonprofits.org/running-nonprofit/fundraising-and-resource-development/charitable-solicitation-registration
21. CharityWatch. "Overhead Ratios Are Essential for Informed Giving" (with BBB Wise Giving Alliance / Charity Navigator program-expense standards and the 2013 "overhead myth" open letter). 2024. https://blog.charitywatch.org/overhead-ratios-are-essential-for-informed-giving/
22. The NonProfit Times. "Investor Makes $4.3 Billion Bid To Take Blackbaud Private" (Blackbaud, Nasdaq: BLKB; Clearlake Capital, ~$80/share). 2024. https://thenonprofittimes.com/npt_articles/investor-makes-4-3-billion-bid-to-take-blackbaud-private/
23. U.S. Securities and Exchange Commission. Blackbaud, Inc. Form 10-K (data-security risk factors). 2026. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001280058&type=10-K
24. Salesforce. Nonprofit Cloud. 2026. https://www.salesforce.com/nonprofit/cloud/
25. PayPal Giving Fund. About Us. 2026. https://www.paypal.com/us/paypal-giving-fund/about
26. Visa and Mastercard investor relations. Annual reports / financial information. 2025. https://investor.visa.com/financial-information/ — https://investor.mastercard.com/financials-and-sec-filings/annual-reports-and-proxy/default.aspx
27. GoFundMe Pro (formerly Classy). Classy Is Now GoFundMe Pro. 2026. https://www.classy.org/
28. Apax Partners. Bonterra. 2026. https://www.apax.com/partnerships/bonterra/
29. Warburg Pincus. Bloomerang Secures Strategic Investment (JMI Equity / Warburg Pincus; Qgiv combination). 2024. https://warburgpincus.com/2024/02/08/bloomerang-secures-strategic-investment-from-leading-private-equity-firm-warburg-pincus-to-accelerate-delivery-of-first-giving-platform/
30. Internal Revenue Service. Life Cycle of a Public Charity — Annual Filing (three-year automatic revocation), Lobbying and Political-Campaign Limits. 2024. https://www.irs.gov/charities-non-profits/charitable-organizations/life-cycle-of-a-public-charity-jeopardizing-exemption
31. U.S. Department of Health and Human Services. HIPAA — Covered Entities and Business Associates. 2024. https://www.hhs.gov/hipaa/for-professionals/covered-entities/index.html
32. U.S. Department of Justice. Herfindahl-Hirschman Index (HHI) — market-concentration thresholds. 2023. https://www.justice.gov/atr/herfindahl-hirschman-index
33. Centers for Disease Control and Prevention, National Center for Health Statistics. Mortality in the United States: Provisional Data, 2024 (heart disease and cancer leading causes of death). 2026. https://www.cdc.gov/nchs/products/databriefs/db548.htm